Thalidomide [clinicaltrials_resource:874d901e28670d3049ab731cb2ec06af]
condition [clinicaltrials_vocabulary:condition]
Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection [clinicaltrials:NCT00000790]A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection [clinicaltrials:NCT00000812]A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer [clinicaltrials:NCT00001446]Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist [clinicaltrials:NCT00001475]Thalidomide to Treat Oral Lesions in HIV-Infected Patients [clinicaltrials:NCT00001524]Pilot Study of Thalidomide to Treat Sjogren's Syndrome [clinicaltrials:NCT00001599]A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus [clinicaltrials:NCT00001680]Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV [clinicaltrials:NCT00002104]A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome [clinicaltrials:NCT00002127]Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome [clinicaltrials:NCT00002157]Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients [clinicaltrials:NCT00002174]A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART [clinicaltrials:NCT00002392]Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers [clinicaltrials:NCT00003754]Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [clinicaltrials:NCT00003850]Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant [clinicaltrials:NCT00003894]clinicaltrials:NCT00004088Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections [clinicaltrials:NCT00004276]Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy [clinicaltrials:NCT00004450]clinicaltrials:NCT00004635clinicaltrials:NCT00004859Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer [clinicaltrials:NCT00004876]Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma [clinicaltrials:NCT00005815]clinicaltrials:NCT00005834Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer [clinicaltrials:NCT00005966]Thalidomide in Treating Patients With Gynecologic Sarcomas [clinicaltrials:NCT00006005]Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed [clinicaltrials:NCT00006006]Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery [clinicaltrials:NCT00006016]Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer [clinicaltrials:NCT00006198]Thalidomide and Dacarbazine for Metastatic Melanoma [clinicaltrials:NCT00006200]Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia [clinicaltrials:NCT00006226]Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor [clinicaltrials:NCT00006358]clinicaltrials:NCT00006890Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma [clinicaltrials:NCT00008242]Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer [clinicaltrials:NCT00009984]Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma [clinicaltrials:NCT00014443]Thalidomide in Treating Patients With Myelofibrosis [clinicaltrials:NCT00015821]Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [clinicaltrials:NCT00015912]Thalidomide in Treating Patients With Myelodysplastic Syndrome [clinicaltrials:NCT00015990]Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer [clinicaltrials:NCT00016224]Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma [clinicaltrials:NCT00017316]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Thalidomide [clinicaltrials_resource:874d901e28670d3049ab731cb2ec06af]
Bio2RDF identifier
874d901e28670d3049ab731cb2ec06af
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:874d901e28670d3049ab731cb2ec06af
identifier
clinicaltrials_resource:874d901e28670d3049ab731cb2ec06af
title
Thalidomide
@en
type
label
Thalidomide [clinicaltrials_resource:874d901e28670d3049ab731cb2ec06af]
@en